Trial · NCT07895394
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Humoral immune response (neutralizing antibody) | 1 month after vaccination | Geometric mean fold rise (GMFR) in RSV-A neutralizing antibody titers from pre-vaccination to 1 month after vaccination, compared between lung transplant recipients and immunocompetent adults. |
| Secondary | Humoral immune response (neutralizing antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean titers (GMTs) in RSV-A neutralizing antibody titers |
| Secondary | Humoral immune response (neutralizing antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean titers (GMTs) in RSV-B neutralizing antibody titers |
| Secondary | Humoral immune response (neutralizing antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in RSV-A neutralizing antibody titers from pre-vaccination levels. |
| Secondary | Humoral immune response (neutralizing antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in RSV-B neutralizing antibody titers from pre-vaccination levels. |
| Secondary | Humoral immune response (RSV specific antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean concentrations (GMCs) in RSVPreF3-specific IgG |
| Secondary | Humoral immune response (RSV specific antibody) | Prevaccination, 1 month and 12 months after vaccination | Geometric mean concentrations (GMCs) in pan-RSV-specific IgG |
| Secondary | Humoral immune response (RSV specific antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in RSVPreF3-specific IgG from pre-vaccination levels. |
| Secondary | Humoral immune response (RSV specific antibody) | 1 month, 12 months after vaccination | Geometric mean fold rises (GMFRs) in pan-RSV-specific IgG from pre-vaccination levels. |
| Secondary | Humoral immune response (serologic response rate) | 1 month, 12 months after vaccination | Proportion of participants with a ≥4-fold increase in antibody levels from pre-vaccination levels |
| Secondary | Cell mediated immunity | 1 month, 12 months after vaccination | Frequency of RSV F-specific CD4+ and CD8+ T cells following stimulation with RSV F peptide pools, measured by flow cytometry. |
| Secondary | Safety (solicited adverse events) | 7 days, 30 days after vaccination | Proportion of participants experiencing solicited local and systemic adverse events following vaccination. |
| Secondary | Safety (unsolicited adverse events, serious adverse events) | Up to 12 months after vaccination | Proportion of participants experiencing unsolicited adverse events or serious adverse events following vaccination. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07895394/registered